Article
Oncology
Kazuma Kishi, Masaki Kuwatani, Yuki Ohnishi, Yasuhiro Kumaki, Hiroyuki Kumeta, Hajime Hirata, Yunosuke Takishin, Ryutaro Furukawa, Kosuke Nagai, Hiroki Yonemura, Shunichiro Nozawa, Ryo Sugiura, Kazumichi Kawakubo, Tomoyasu Aizawa, Naoya Sakamoto
Summary: A metabolomic analysis of duodenal juice was performed to identify differences between malignant and benign biliary diseases, demonstrating the potential of duodenal juice metabolomics as a diagnostic biomarker for biliary diseases.
Review
Medicine, General & Internal
Shunsuke Kato
Summary: The prognosis of patients with solid tumors has been significantly improved with the development of molecular-targeted drugs and immune checkpoint inhibitors. However, pancreatic cancer and biliary tract cancer still have lower survival rates compared to other carcinomas. The Cancer Genome Atlas (TCGA) project has identified various driver mutations, leading to basket trials targeting these mutations regardless of the primary organ.
Review
Gastroenterology & Hepatology
Weifeng Zeng, Ruiqi Mao, Zhanguo Zhang, Xiaoping Chen
Summary: Biliary tract cancers (BTCs) have a poor prognosis and surgery is the only curative therapy. Currently, chemotherapy is the main treatment, but many patients develop resistance. Therefore, targeted therapy and immunotherapy have become important strategies to improve patient outcomes.
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY
(2023)
Article
Oncology
Fei Su, Ziyu Gao, Yueyang Liu, Guiqin Zhou, Wei Gao, Chao Deng, Yuyu Liu, Yihao Zhang, Xiaoyan Ma, Yongxia Wang, Lili Guan, Yafang Zhang, Baoquan Liu
Summary: This study utilizes serum microRNAs as biomarkers to identify high risk individuals with early biliary tract cancer. By integrating various analysis methods, four key synergistic biomarkers were identified and their diagnostic performance for BTC was demonstrated.
FRONTIERS IN ONCOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Davide Ciardiello, Brigida Anna Maiorano, Paola Parente, Maria Grazia Rodriquenz, Tiziana Pia Latiano, Cinzia Chiarazzo, Valerio Pazienza, Luigi Pio Guerrera, Brunella Amoruso, Nicola Normanno, Giulia Martini, Fortunato Ciardiello, Erika Martinelli, Evaristo Maiello
Summary: Biliary tract cancers (BTC) are aggressive tumors with limited therapeutic options. Recent advances in understanding its molecular landscape have provided new possibilities for immunotherapy, but challenges remain. This review critically analyzes completed trials and discusses future directions and potential predictive biomarkers.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Medicine, General & Internal
Junya Toyoda, Kota Sahara, Tomoaki Takahashi, Kentaro Miyake, Yasuhiro Yabushita, Yu Sawada, Yuki Homma, Ryusei Matsuyama, Itaru Endo, Timothy M. Pawlik
Summary: Neoadjuvant therapy (NAT) did not improve overall survival in patients with extrahepatic biliary tract cancer (EBTC), but showed improved survival in patients with advanced-stage disease.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Oncology
Nduka Ofoeyeno, Emmanuel Ekpenyong, Chiara Braconi
Summary: Non-coding ribonucleic acid (RNA) plays crucial roles in the pathogenesis and clinical implications of biliary tract cancer (BTC), particularly through the regulation of mRNA transcriptomes. MicroRNAs have been shown to have significant roles in BTC progression, offering potential as biomarkers and therapeutics, but further research and technological advancements are needed before they can be implemented in clinical practice.
Review
Oncology
Yue Wang, Tianli Chen, Kangshuai Li, Wentao Mu, Zengli Liu, Anda Shi, Jialiang Liu, Wei Zhao, Shuo Lian, Shaohui Huang, Chang Pan, Zongli Zhang
Summary: The article summarizes the latest advances in antiangiogenic therapy for biliary tract cancers, focusing on the molecular mechanisms and therapeutic effects, while highlighting the uncertainty surrounding the effectiveness of antiangiogenic therapy.
FRONTIERS IN ONCOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Weixun Chen, Zhengnan Hu, Jia Song, Yu Wu, Bixiang Zhang, Lei Zhang
Summary: Biliary tract cancers (BTCs) are aggressive tumors with poor prognosis. Surgery, chemotherapy, targeted therapy, and immunotherapy are the main treatment options. The genetic background of each cholangiocarcinoma subtype has been described, enabling precision medicine in targeted therapies. Immunotherapy, including immune checkpoint inhibitors, shows promise in a subset of patients. Adoptive cell therapy is a potential approach, but further clinical trials are needed. This review provides an overview of BTC treatment and compares the different treatment options.
FRONTIERS IN BIOSCIENCE-LANDMARK
(2022)
Article
Medicine, General & Internal
Yueting Han, Haiyang Zhang, Zhengyang Zhou, Rui Liu, Dongying Liu, Ming Bai, Qian Fan, Jialu Li, Kegan Zhu, Hongli Li, Tao Ning, Guoguang Ying, Yi Ba
Summary: The study identified five significantly upregulated miRNAs in the serum of BTCs patients, with miR-221 serving as an early diagnostic marker and miR-10a, miR-21, miR-135b, and miR-214 being potential biomarkers for biliary diseases diagnosis.
INTERNATIONAL JOURNAL OF GENERAL MEDICINE
(2021)
Review
Medical Laboratory Technology
Fusheng Liu, Xingyuan Hao, Bin Liu, Songmei Liu, Yufeng Yuan
Summary: Biliary tract cancers are heterogeneous in etiology, morphology, and molecular characteristics. Liquid biopsy provides a unique and minimally invasive approach to understand tumor biology, monitor disease progression, and analyze tumor genetic profiles in real-time. Bile, as a promising biological fluid, can be utilized for liquid biopsy by examining various components such as cells, extracellular vesicles, nucleic acids, proteins, and metabolites.
CLINICA CHIMICA ACTA
(2023)
Review
Oncology
Xiuqiong Chen, Fanqiao Meng, Hua Xiong, Yanmei Zou
Summary: The study found that gemcitabine (GEM) is considered the optimal adjuvant therapy for biliary tract cancer (BTC) patients, and chemoradiotherapy (CRT) may be the best treatment approach for R+ and N+ patients. Additionally, 5-fluorouracil (5-FU) showed better efficacy in certain situations compared to other therapies.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Caiyun Nie, Huifang Lv, Yishu Xing, Beibei Chen, Weifeng Xu, Jianzheng Wang, Xiaobing Chen
Summary: Apatinib monotherapy or combination therapy can improve PFS in patients with advanced or recurrent BTC, and adverse reactions can be well tolerated.
Review
Gastroenterology & Hepatology
Fredy Nehme, Jeffrey H. Lee
Summary: Pancreatic adenocarcinoma is a leading cause of cancer-related morbidity and mortality with most patients presenting with advanced disease. Preoperative biliary drainage (PBD) has traditionally been used to improve surgical outcomes, but recent data suggests potential increased complications with systematic PBD. Indications for PBD include cholangitis, delayed surgery, and jaundice relief in patients planned to receive neoadjuvant therapy. Endoscopic retrograde cholangiopancreatography is the preferred method for PBD, with self-expanding metal stents shown to be cost-effective and safe compared to plastic stents.
DIGESTIVE ENDOSCOPY
(2022)
Review
Oncology
Xin Yan, Huimin Zou, Yunfeng Lai, Carolina Oi Lam Ung, Hao Hu
Summary: Through a meta-analysis of all clinical trials of first-line combination therapies for advanced biliary tract cancer, we concluded that combining immunotherapy with chemotherapies could improve the survival of aBTC patients by increasing the objective response rate.
Article
Gastroenterology & Hepatology
Carlo Sposito, Francesca Ratti, Alessandro Cucchetti, Francesco Ardito, Andrea Ruzzenente, Stefano Di Sandro, Marianna Maspero, Giorgio Ercolani, Fabrizio Di Benedetto, Alfredo Guglielmi, Felice Giuliante, Luca Aldrighetti, Vincenzo Mazzaferro
Summary: This study aimed to determine whether lymphadenectomy improves long-term outcomes in patients with clinically node-negative intrahepatic cholangiocarcinoma (iCCA). The results showed that adequate lymphadenectomy significantly improved survival outcomes for patients with clinically node-negative iCCA who were found to be node-positive at pathology. Therefore, routine use of adequate lymphadenectomy is recommended for patients with clinically node-negative iCCA.
JOURNAL OF HEPATOLOGY
(2023)
Article
Surgery
Vittoria Matilde Piva, Maria Caterina De Grandis, Irene Sole Zuin, Valentina Angerilli, Floriana Nappo, Rita Alfieri, Selma Ahcene Djaballah, Sabina Murgioni, Francesca Bergamo, Matteo Fassan, Michele Valmasoni, Sara Lonardi
Summary: This review summarizes the current evidence on the use of liquid biopsy in gastroesophageal cancer, focusing on the detection of ctDNA in the postoperative setting and its potential role as a guide for treatment decision.
UPDATES IN SURGERY
(2023)
Article
Oncology
Mara Persano, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, Jose Presa Ramos, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Bernardo Stefanini, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Margarida Montes, Caterina Vivaldi, Caterina Solda, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Valentina Burgio, Angelo Della Corte, Francesca Ratti, Francesco De Cobelli, Luca Aldrighetti, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini
Summary: This real-world study investigates the association between the prognostic nutritional index (PNI) and clinical outcomes in HCC patients treated with atezolizumab plus bevacizumab. The study shows that high PNI is associated with longer overall survival and progression-free survival.
Article
Oncology
Mario Caccese, Anna Maria Saieva, Valentina Guarneri, Sara Lonardi, Massimo Cacco, Vanna Chiarion Sileni, Michele Gottardi, Eleonora Mioranza, Francesca Bergamo, Antonella Brunello, Vittorina Zagonel, Patrizia Benini
Summary: Routine testing for SARS-CoV-2 in asymptomatic and fully vaccinated cancer patients during treatment did not appear to be cost-effective. Out of 2439 cancer patients screened, only 2.17% tested positive, and 92.5% had their cancer treatment discontinued as a precaution.
Article
Oncology
Alessandro Cucchetti, Omar Elshaarawy, Guohong Han, Charing C. N. Chong, Carla Serra, Joanne Marie O'Rourke, Richard Crew, Cristina Felicani, Giorgio Ercolani, Tahir Shah, Arndt Vogel, Paul B. S. Lai, Philip J. Johnson
Summary: This study developed a statistical model to predict cure after ablation and compared the curative potential of different therapies. The cure fraction for HCC treated with ablation was found to be around 20% to 30%, similar to resection but inferior to transplantation.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Francesco Pierantoni, Michele Dionese, Umberto Basso, Eleonora Lai, Nicolo Cavasin, Elisa Erbetta, Alvise Mattana, Davide Bimbatti, Vittorina Zagonel, Sara Lonardi, Marco Maruzzo
Summary: Analyzing clinical data of 72 mUC patients treated with ICIs, we found that fT3/fT4 ratio is a strong prognostic factor for progression-free survival and overall survival. The prognostic role of fT3/fT4 ratio is independent from other established prognostic factors.
CLINICAL GENITOURINARY CANCER
(2023)
Article
Oncology
Margherita Rimini, Mara Persano, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, Jose Presa, Francesca Salani, Sara Lonardi, Fabio Piscaglia, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Marta Schirripa, Margarida Montes, Caterina Vivaldi, Caterina Solda, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Valentina Burgio, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini
Summary: This study analyzed the efficacy of atezolizumab plus bevacizumab versus Lenvatinib as first-line treatment for patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh (CP) class B. The results showed that Lenvatinib had a longer overall survival (OS) compared to atezolizumab plus bevacizumab in patients with CP B HCC.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Roberto Moretto, Daniele Rossini, Aurelie Catteau, Carlotta Antoniotti, Mirella Giordano, Alessandra Boccaccino, Clara Ugolini, Agnese Proietti, Veronica Conca, Alboukadel Kassambara, Filippo Pietrantonio, Lisa Salvatore, Sara Lonardi, Stefano Tamberi, Emiliano Tamburini, Anello Marcello Poma, Jacques Fieschi, Gabriella Fontanini, Gianluca Masi, Jerome Galon, Chiara Cremolini
Summary: The expression of tumor-infiltrating lymphocytes (TILs), Immunoscore, Immunoscore-IC, and programmed death ligand-1 (PD-L1) can predict the efficacy of immune-checkpoint inhibitors (ICIs) in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Giovanni Randon, Yu Aoki, Romain Cohen, Leonardo Provenzano, Vincenzo Nasca, Samuel J. Klempner, Steven B. Maron, Riccardo Cerantola, Joseph Chao, Lorenzo Fornaro, Walter Ferrari Bravo, Filippo Ghelardi, Margherita Ambrosini, Paolo Manca, Massimiliano Salati, Akihito Kawazoe, Valerie Zhu, Darren Cowzer, Virginia Genovesi, Sara Lonardi, Kohei Shitara, Thierry Andre, Filippo Pietrantonio
Summary: This study found that immune checkpoint inhibitor-based therapy is superior to chemotherapy in patients with dMMR and/or MSI-high advanced gastric or gastroesophageal junction adenocarcinoma. However, more studies are needed to examine prognostic features within this patient population.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Andrea Casadei-Gardini, Francesco Leone, Giovanni Brandi, Mario Scartozzi, Nicola Silvestris, Daniele Santini, Luca Faloppi, Massimo Aglietta, Maria Antonietta Satolli, Alessandro Rizzo, Sara Lonardi, Giuseppe Aprile, Lorenzo Fornaro
Summary: Cholangiocarcinoma is a rare tumor that affects the liver biliary tree with poor prognosis. This study analyzed a large dataset of cholangiocarcinoma patients receiving systemic chemotherapy over a period of almost 20 years to understand their survival trends.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Paolo Manca, Francesca Corti, Rossana Intini, Giacomo Mazzoli, Rosalba Miceli, Marco Maria Germani, Francesca Bergamo, Margherita Ambrosini, Eleonora Cristarella, Riccardo Cerantola, Chiara Boccaccio, Gianmarco Ricagno, Filippo Ghelardi, Giovanni Randon, Giuseppe Leoncini, Massimo Milione, Matteo Fassan, Chiara Cremolini, Sara Lonardi, Filippo Pietrantonio
Summary: Immune checkpoint inhibitors (ICIs) are the standard treatment for patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC). Tumour mutational burden (TMB) is a promising biomarker for predicting treatment outcomes.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Lorenzo Fornaro, Sara Lonardi, Silvia Catanese, Floriana Nappo, Filippo Pietrantonio, Antonio Pellino, Valentina Angerilli, Francesca Signorini, Francesca Salani, Sabina Murgioni, Ioana Ancuta Neculaescu, Rossella Bruno, Caterina Vivaldi, Gianmarco Ricagno, Gianluca Masi, Francesca Bergamo, Clara Ugolini, Matteo Fassan
Summary: Different methods of evaluation for mismatch repair proteins and microsatellite instability-high (MSI-H) status in gastric and gastroesophageal adenocarcinoma can lead to inconsistent results between endoscopic biopsies and surgical samples. Strategies to improve reliability of assessment should focus on tissue collection and management during endoscopy, as well as training of dedicated gastrointestinal pathologists within the multidisciplinary team.
Article
Gastroenterology & Hepatology
Alessandro Cucchetti, Philip Johnson, Gabriele Capurso, Stefano Crippa, Carlo Alberto Pacilio, Carlo Fabbri, Massimo Falconi, Giorgio Ercolani
Summary: The aim of this study was to explore the correlation between incidence and mortality of pancreatic cancer and healthcare indicators in 36 European countries. The results showed that both incidence and mortality were increasing, and they were strongly positively correlated. Higher health expenditure, availability of beds and medical technology, as well as the number of practicing doctors were related to higher incidence. On the other hand, lower mortality was associated with indicators such as outpatient curative care expenditure, the number of pet scanners, and radiation therapy equipment. The study highlights the impact of healthcare environment on pancreatic cancer incidence and mortality.
Article
Surgery
L. Solaini, D. Cavaliere, G. Rocco, A. Avanzolini, D. Di Pietrantonio, G. Ercolani
Summary: The study aims to analyze the learning curve of each step of robotic transabdominal pre-peritoneal inguinal hernia repair (rTAPP) in two surgeons with varying degrees of expertise with the robotic platform but no experience with laparoscopic hernia repair. It was found that there was a learning phase followed by a gradual improvement in operative time and outcomes. The learning phase of rTAPP surgery may vary between 20 and 35 cases, depending on the surgeon's experience in robotic surgery.